2023 ASCO中國之聲｜胃食管與肝膽胰腫瘤領域壁報部分共37項中國研究入選！

一年一度的全球腫瘤界盛會-美國臨床腫瘤學會（ASCO）年會將于當地時間6月2日-6月6日召開。ASCO年會是世界上規模最大、學術水平最高、最具權威的臨床腫瘤學會議，致力于癌癥的預防、治療和改善患者管理，以展示腫瘤的基礎研究和臨床最新研究為特點，討論當前國際先進的治療方法。

隨著中國臨床研究在腫瘤領域的快速成長，中國在世界腫瘤領域中也發揮著日益重要的作用。此次會議上，中國胃食管與肝膽胰腫瘤領域Poster Session共入選37項。期待中國專家在ASCO年會上展現風采！

標題：A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

報告人：黃鏡

單位：中國醫學科學院腫瘤醫院

標題：A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data.

報告人：季加孚

單位：北京大學腫瘤醫院

標題：EpCAM CAR T (IMC001) for the treatment of advanced GI cancers.

報告人：Guoqiang Ai

單位：Suzhou Immunofoco Biotechnology Co., Ltd

標題：Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.

報告人：Xiaoting Ma

單位：中國醫學科學院腫瘤醫院

標題：Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.

報告人：Zhiye Zhang

單位：河南科技大學第一附屬醫院

標題：Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

報告人：沈琳

單位：北京大學腫瘤醫院

標題：Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).

報告人：Guangyu Yao

單位：復旦大學附屬中山醫院

標題：Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.

報告人：弓磊

單位：天津醫科大學腫瘤醫院

標題：Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).

報告人：魯智豪

單位：北京大學腫瘤醫院

標題：Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.

報告人：俞鵬飛

單位：浙江省腫瘤醫院

標題：Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).

報告人：陳寶清

單位：中山大學腫瘤防治中心

標題：Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.

報告人：Lizhen Wang

單位：羅氏(中國)投資有限公司

標題：Multi-dimensional cell-free DNA-based liquid biopsy and early detection of gastric cancer.

報告人：俞鵬飛

單位：浙江省腫瘤醫院

標題：Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.

報告人：習勉

單位：中山大學腫瘤防治中心

標題：Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.

報告人：張仁泉

單位：安徽醫科大學第一附屬醫院

標題：Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.

報告人：Peng Jin

單位：山東省腫瘤醫院

標題：GaEsSeer: Early detection of gastric and esophageal cancer by integrating methylation and fragmentomics signatures in cfDNA.

報告人：鐘蕓詩

單位：復旦大學附屬中山醫院

標題：Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.

報告人：何文卓

單位：中山大學腫瘤防治中心

標題：Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

報告人：張志波

單位：福建醫科大學附屬第一醫院

標題：An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

報告人：畢鋒

單位：四川大學華西醫院

標題：Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

報告人：李金鵬

單位：山東第一醫科大學

標題：Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.

報告人：袁振剛

單位：上海東方肝膽外科醫院

標題：Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.

報告人：Yi Zheng

單位：浙江大學醫學院附屬第一醫院

標題：A prospective, open-label, randomized, controlled trial of radiofrequency ablation versus stereotactic body radiation therapy for recurrent small hepatocellular carcinoma.

報告人：張耀軍

單位：中山大學腫瘤防治中心

標題：Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.

報告人：Zijie Zhang

單位：上海交通大學醫學院附屬仁濟醫院

標題：Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study.

報告人：Le Li

單位：廣西醫科大學附屬腫瘤醫院

標題：Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

報告人：崔云龍

單位：天津醫科大學腫瘤醫院

標題：Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.

報告人：Baojiang Liu

單位：北京大學腫瘤醫院

標題：Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.

報告人：Chi Leung Chiang

單位：香港大學

標題：A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

報告人：周儉

單位：復旦大學附屬中山醫院

標題：Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.

報告人：Rui Liu

單位：江蘇鹍遠生物技術有限公司

標題：The efficacy of radical hepatectomy versus stereotactic body radiotherapy for primary hepatocellular carcinoma: A propensity score matching analysis.

報告人：Yulin Hu

單位：深圳大學

標題：A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

報告人：Haiyan Si

單位：中國人民解放軍總醫院第五醫學中心

標題：PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with borderline resectable and locally advanced pancreatic cancer: A biomolecular exploratory, single-arm phase II clinical trial.

報告人：杜娟

單位：南京大學醫學院附屬鼓樓醫院

標題：Detection and localization of gastrointestinal cancers based on multi-dimentional signatures from a single cfDNA targeted sequencing assay.

報告人：楊欣榮

單位：復旦大學附屬中山醫院

標題：NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.

報告人：Xiaodong Wang

單位：北京大學腫瘤醫院